Mycobacterium tuberculosis

Overview

Mycobacterium tuberculosis is the bacterial pathogen responsible for tuberculosis (TB), a major global infectious disease that primarily affects the lungs but can also disseminate to other organs. It is an intracellular, slow-growing mycobacterium with a distinctive cell envelope and a strong capacity to persist within host macrophages, which contributes to chronic infection, immune evasion, and prolonged treatment requirements. In biomedical research, M. tuberculosis is commonly abbreviated as Mtb or MTB.

The organism is a central target in anti-tubercular drug discovery, vaccine development, host-directed therapy, and diagnostic research. Its biology is studied through virulence factors, metabolic pathways, and strain-specific differences, including drug-sensitive and drug-resistant isolates. Recent work has also focused on antigenic targets such as Ag85B and PstS1, essential enzymes and pathways such as InhA and biotin biosynthesis, and host-pathogen interactions involving macrophage survival, ferroptosis, and inflammatory signaling.

Recent Publications Summary

Recent studies on Mycobacterium tuberculosis have focused on identifying new drug targets, improving delivery systems, and reducing the emergence of resistance. A metagenome-guided natural product discovery platform, resistance-CONKAT-seq, linked a soil metagenomic biosynthetic gene cluster to a potential clpP self-resistance gene and led to the discovery of metaze B, which inhibited the M. tuberculosis ClpP proteolytic subunit with an IC50 of 1.35 μM 42366525Jun. In parallel, medicinal chemistry efforts produced bifunctional β-lactams designed to release 4-aminoindole upon hydrolytic opening of the β-lactam ring; these compounds showed good antitubercular potency, were rescued by exogenous l-tryptophan, and generated resistant mutants at a much lower frequency than the parent indole 4-carboxamides 42262488Jun.

Other work explored host-directed and dual-action approaches against M. tuberculosis. Guanilated quinolones were investigated as dual inhibitors of Janus Kinase 3 and M. tuberculosis, with compound 13 showing 98% enzyme inhibition at 1 μM and antitubercular activity in the 0.2–6 μM range in two growth media 42202039May. A separate study developed lesion-pathogen dual-targeting theranostic nanoparticles (ICG-PEG-Tar) that combined fluorescence/photothermal imaging with an anti-Ag85B antibody to target M. tuberculosis antigen 85B; binding specificity was confirmed by ELISA, and therapeutic efficacy was evaluated in a murine tail granuloma model induced by Mycobacterium marinum as a surrogate for tuberculosis 42133291May. Another nanoparticle-based approach loaded an MS10-Trunc aptamer, designed to inhibit M. tuberculosis malate synthase, into monoolein-based cationic cubosomes to improve aptamer delivery for tuberculosis treatment 42117503May.

Several publications addressed resistance, metabolism, and vaccine development in M. tuberculosis. A machine-learning study used whole-genome sequencing data from clinical isolates to predict bedaquiline resistance, achieving accuracies of 83.60% with a multilayer perceptron and 79.64% with random forest, and identifying mutations and 15 new antibiotic-resistant genes associated with resistance 42061986Apr. In biotin biosynthesis, optimized piperazine-based BioA inhibitors were synthesized and tested against isogenic strains, with C48 emerging as the most potent candidate and showing MICs of 0.012–0.093 μM against drug-sensitive and drug-resistant M. tuberculosis strains 42017700Apr. On the vaccine side, rational deletion of virulence-related genes produced triple and quadruple knockout M. tuberculosis strains, including TKO-Z, TKO-D, and QKO constructs, which were evaluated for immunogenicity and safety in mice 42012295Apr.

Mechanistic studies also linked M. tuberculosis survival to host cell pathways. Pyrvinium pamoate, an FDA-approved anthelminthic, was reported to reduce intracellular M. tuberculosis survival in infected macrophages at low dose by suppressing macrophage ferroptosis; the drug bound casein kinase 1α and reduced M. tuberculosis- or RSL3-induced lipid peroxidation ferroptosis through effects on the ATF4-xCT-GSH-GPX4 axis and YAP1 signaling 41875752Mar.

What Changes, What Holds

1. New inhibitors and resistance-sparing scaffolds expand the drug-target map without displacing the established view of Mtb as a drug-discovery focus
REINFORCES Metaze B adds ClpP proteolysis to the growing list of actionable M. tuberculosis vulnerabilities, while the bifunctional β-lactams support the idea that prodrug-like design can improve potency and lower resistance frequency. Together, these findings strengthen the baseline emphasis on virulence and metabolic targets, but they do not overturn it; they mainly broaden the set of candidate chemotypes and mechanisms under active exploration 42366525Jun42262488Jun.

2. Host-directed and dual-target delivery strategies broaden how Mtb is being attacked, but they do not replace direct antibacterial targeting
NEW DIRECTION Guanilated quinolones and the nanoparticle platforms point to a more integrated therapeutic model in which M. tuberculosis is addressed alongside host signaling, lesion localization, or antigen targeting. That extends the baseline’s host-pathogen interaction theme, yet the Overview does not already assign Mtb a role in dual-action kinase inhibition or theranostic delivery, so these are additions rather than corrections 42202039May42133291May.

3. Resistance prediction, BioA inhibition, and attenuated-strain design sharpen existing priorities rather than changing them
REINFORCES Machine-learning prediction of bedaquiline resistance strengthens the established focus on drug-resistant isolates and diagnostics, while the BioA inhibitor work reinforces biotin biosynthesis as a validated metabolic target. The engineered knockout strains likewise fit the ongoing vaccine-development agenda. None of these findings displace the baseline account; they make it more actionable by improving resistance surveillance, target validation, and candidate vaccine design 42061986Apr42017700Apr.

4. Suppressing macrophage ferroptosis emerges as a host-directed way to limit intracellular Mtb survival
NEW DIRECTION Pyrvinium pamoate links reduced intracellular M. tuberculosis burden to inhibition of macrophage ferroptosis, which adds a specific host-cell death pathway to the baseline’s broader mention of macrophage survival and inflammatory signaling. The Overview already recognizes host-pathogen interactions, but it does not name ferroptosis as a therapeutic lever; this work therefore extends the account by identifying a mechanistically distinct host-directed intervention 41875752Mar.

Overview update candidates: ClpP inhibition as a new drug target; host-directed suppression of macrophage ferroptosis as a therapeutic strategy.